129 related articles for article (PubMed ID: 3604394)
41. Characterization of immunogenic properties of haptenated liposomal model membranes in mice. V. Effect of membrane composition on humoral and cellular immunogenicity.
van Houte AJ; Snippe H; Schmitz MG; Willers JM
Immunology; 1981 Nov; 44(3):561-8. PubMed ID: 7033115
[TBL] [Abstract][Full Text] [Related]
42. Studies on adjuvants for human prophylactics. II. Influence of the route of injection on the activity of adjuvants to tetanus toxoid in guinea pigs.
Yamamoto A; Murata R
Jpn J Med Sci Biol; 1978; 31(5-6):393-406. PubMed ID: 156804
[TBL] [Abstract][Full Text] [Related]
43. Liposomes for drug delivery to the lungs by nebulization.
Zaru M; Mourtas S; Klepetsanis P; Fadda AM; Antimisiaris SG
Eur J Pharm Biopharm; 2007 Nov; 67(3):655-66. PubMed ID: 17540552
[TBL] [Abstract][Full Text] [Related]
44. Liposomes containing NY‑ESO‑1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines.
Cruz LJ; Rueda F; Simón L; Cordobilla B; Albericio F; Domingo JC
Nanomedicine (Lond); 2014 Apr; 9(4):435-49. PubMed ID: 24910875
[TBL] [Abstract][Full Text] [Related]
45. Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes.
El-Nesr OH; Yahiya SA; El-Gazayerly ON
Saudi Pharm J; 2010 Oct; 18(4):217-24. PubMed ID: 23960730
[TBL] [Abstract][Full Text] [Related]
46. The involvement of the lipid phase transition in the plasma-induced dissolution of multilamellar phosphatidylcholine vesicles.
Scherphof G; Morselt H; Regts J; Wilschut JC
Biochim Biophys Acta; 1979 Sep; 556(2):196-207. PubMed ID: 534623
[TBL] [Abstract][Full Text] [Related]
47. Mucosal Adjuvant Potential of Quillaja saponins and Cross-linked Dextran Microspheres, Co-administered with Liposomes Encapsulated with Tetanus Toxoid.
Moghadam Ariaee F; Tafaghodi M
Iran J Pharm Res; 2012; 11(3):723-32. PubMed ID: 24250499
[TBL] [Abstract][Full Text] [Related]
48. Physicochemical and immunological properties of albumin-associated dialkyl-ether phosphatidylcholine liposomes.
Shek PN; Yung BY; Stanacev NZ
Biochim Biophys Acta; 1986 Feb; 855(1):33-40. PubMed ID: 3942744
[TBL] [Abstract][Full Text] [Related]
49. Entrapment of haemoglobin into liposomes by the dehydration-rehydration method: vesicle characterization and in vivo behaviour.
Brandl M; Gregoriadis G
Biochim Biophys Acta; 1994 Nov; 1196(1):65-75. PubMed ID: 7986812
[TBL] [Abstract][Full Text] [Related]
50. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide.
Schroit AJ; Fidler IJ
Cancer Res; 1982 Jan; 42(1):161-7. PubMed ID: 7053846
[TBL] [Abstract][Full Text] [Related]
51. Liposomes act as effective biolubricants for friction reduction in human synovial joints.
Sivan S; Schroeder A; Verberne G; Merkher Y; Diminsky D; Priev A; Maroudas A; Halperin G; Nitzan D; Etsion I; Barenholz Y
Langmuir; 2010 Jan; 26(2):1107-16. PubMed ID: 20014818
[TBL] [Abstract][Full Text] [Related]
52. Oral immunization against diphtheria and tetanus infections by fluid diphtheria and tetanus toxoids.
Mirchamsy H; Hamedi M; Fateh G; Sassani A
Vaccine; 1994 Oct; 12(13):1167-72. PubMed ID: 7530887
[TBL] [Abstract][Full Text] [Related]
53. Stabilization of tetanus toxoid formulation containing aluminium hydroxide adjuvant against freeze-thawing.
Solanki VA; Jain NK; Roy I
Int J Pharm; 2011 Jul; 414(1-2):140-7. PubMed ID: 21605644
[TBL] [Abstract][Full Text] [Related]
54. Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying.
Christensen D; Foged C; Rosenkrands I; Nielsen HM; Andersen P; Agger EM
Biochim Biophys Acta; 2007 Sep; 1768(9):2120-9. PubMed ID: 17555704
[TBL] [Abstract][Full Text] [Related]
55. Early and enhanced antioxin responses elicited with complexes of tetanus toxoid and specific mouse and human antibodies.
Stoner RD; Terres G; Hess MW
J Infect Dis; 1975 Mar; 131(3):230-8. PubMed ID: 47882
[TBL] [Abstract][Full Text] [Related]
56. Carrier and adjuvant properties of liposome-borne tumor-specific antigens.
LeGrue SJ
Cancer Immunol Immunother; 1984; 17(2):135-41. PubMed ID: 6565518
[TBL] [Abstract][Full Text] [Related]
57. Development of novel fusogenic vesosomes for transcutaneous immunization.
Mishra V; Mahor S; Rawat A; Dubey P; Gupta PN; Singh P; Vyas SP
Vaccine; 2006 Jul; 24(27-28):5559-70. PubMed ID: 16730102
[TBL] [Abstract][Full Text] [Related]
58. In vivo stability of ester- and ether-linked phospholipid-containing liposomes as measured by perturbed angular correlation spectroscopy.
Derksen JT; Baldeschwieler JD; Scherphof GL
Proc Natl Acad Sci U S A; 1988 Dec; 85(24):9768-72. PubMed ID: 3200855
[TBL] [Abstract][Full Text] [Related]
59. [Effects of liposomes formulation and preparation method on the stability of acyclovir palmitate liposomes].
Liu H; Tang R; He XX; Zhang Y
Yao Xue Xue Bao; 2002 Jul; 37(7):563-6. PubMed ID: 12914330
[TBL] [Abstract][Full Text] [Related]
60. Pluronic F127-based systemic vaccine delivery systems.
Coeshott CM; Smithson SL; Verderber E; Samaniego A; Blonder JM; Rosenthal GJ; Westerink MA
Vaccine; 2004 Jun; 22(19):2396-405. PubMed ID: 15193401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
